SCHEMBL25867898

SCHEMBL25867898

CC(C)NC(Cc1cc2ccccc2[nH]1)C(=O)C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.51
MTNR1A P48039 1/20 0.48
MTNR1B P49286 1/20 0.48
PYGL P06737 1/20 0.42
PIN1 Q13526 3/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
CASR P41180 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NLRP3 Q96P20 1/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12766237 1.00 ADAMTS4 (0.51) ADAMTS4MTNR1AMTNR1BPYGLPIN1
SCHEMBL28952692 0.88 ADAMTS4 (0.61) ADAMTS4MTNR1AMTNR1BPYGLPIN1
SCHEMBL25885232 0.88 MTNR1A (0.52) ADAMTS4MTNR1AMTNR1BPYGLPIN1
SCHEMBL22525256 0.77 ADAMTS4 (0.64) ADAMTS4MTNR1AMTNR1BPYGLPIN1
SCHEMBL16656704 0.77 MTNR1A (0.55) ADAMTS4MTNR1AMTNR1BPYGLPIN1
SCHEMBL14614675 0.76 ADAMTS4 (0.53) ADAMTS4MTNR1AMTNR1BPYGLPIN1
SCHEMBL17943265 0.75 NPC1 (0.50) LMNAL3MBTL1TSHRRAB9A
SCHEMBL12766328 0.75 NPC1 (0.50) LMNAL3MBTL1TSHRRAB9A
SCHEMBL7601946 0.75 NPC1 (0.50) LMNAL3MBTL1TSHRRAB9A
SCHEMBL5159413 0.75 ADAMTS4 (0.54) ADAMTS4MTNR1AMTNR1BPYGLPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A ADAMTS4 818/4885MTNR1A 2282/4885MTNR1B 1868/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A ADAMTS4 3612/4885MTNR1A 904/4885MTNR1B 647/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R ADAMTS4 926/4885MTNR1A 967/4885MTNR1B 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.